These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17947521)

  • 1. Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.
    Tarr AW; Owsianka AM; Jayaraj D; Brown RJP; Hickling TP; Irving WL; Patel AH; Ball JK
    J Gen Virol; 2007 Nov; 88(Pt 11):2991-3001. PubMed ID: 17947521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.
    Tarr AW; Owsianka AM; Timms JM; McClure CP; Brown RJ; Hickling TP; Pietschmann T; Bartenschlager R; Patel AH; Ball JK
    Hepatology; 2006 Mar; 43(3):592-601. PubMed ID: 16496330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
    Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
    J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge.
    Desombere I; Fafi-Kremer S; Van Houtte F; Pessaux P; Farhoudi A; Heydmann L; Verhoye L; Cole S; McKeating JA; Leroux-Roels G; Baumert TF; Patel AH; Meuleman P
    Hepatology; 2016 Apr; 63(4):1120-34. PubMed ID: 26710081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.
    Owsianka A; Tarr AW; Juttla VS; Lavillette D; Bartosch B; Cosset FL; Ball JK; Patel AH
    J Virol; 2005 Sep; 79(17):11095-104. PubMed ID: 16103160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody.
    Potter JA; Owsianka AM; Jeffery N; Matthews DJ; Keck ZY; Lau P; Foung SK; Taylor GL; Patel AH
    J Virol; 2012 Dec; 86(23):12923-32. PubMed ID: 22993159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
    Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
    J Virol; 2018 May; 92(9):. PubMed ID: 29467319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.
    Ruwona TB; Giang E; Nieusma T; Law M
    J Virol; 2014 Sep; 88(18):10459-71. PubMed ID: 24965471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
    Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
    J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
    Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
    J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
    Desombere I; Mesalam AA; Urbanowicz RA; Van Houtte F; Verhoye L; Keck ZY; Farhoudi A; Vercauteren K; Weening KE; Baumert TF; Patel AH; Foung SKH; Ball J; Leroux-Roels G; Meuleman P
    Antiviral Res; 2017 Dec; 148():53-64. PubMed ID: 29074219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants.
    Khera T; Behrendt P; Bankwitz D; Brown RJP; Todt D; Doepke M; Khan AG; Schulze K; Law J; Logan M; Hockman D; Wong JAJ; Dold L; Gonzalez-Motos V; Spengler U; Viejo-Borbolla A; Ströh LJ; Krey T; Tarr AW; Steinmann E; Manns MP; Klein F; Guzman CA; Marcotrigiano J; Houghton M; Pietschmann T
    J Hepatol; 2019 Apr; 70(4):593-602. PubMed ID: 30439392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation and Characterization of Monoclonal Antibodies against a Cyclic Variant of Hepatitis C Virus E2 Epitope 412-422.
    Sandomenico A; Leonardi A; Berisio R; Sanguigno L; Focà G; Focà A; Ruggiero A; Doti N; Muscariello L; Barone D; Farina C; Owsianka A; Vitagliano L; Patel AH; Ruvo M
    J Virol; 2016 Jan; 90(7):3745-59. PubMed ID: 26819303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.
    Hadlock KG; Lanford RE; Perkins S; Rowe J; Yang Q; Levy S; Pileri P; Abrignani S; Foung SK
    J Virol; 2000 Nov; 74(22):10407-16. PubMed ID: 11044085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus.
    Ahsan A; Dar S; Hassan F; Ghafoor F; Yousuf MH; Shahzad-Ul-Hussan S
    PLoS One; 2021; 16(8):e0256816. PubMed ID: 34449828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.
    Owsianka AM; Tarr AW; Keck ZY; Li TK; Witteveldt J; Adair R; Foung SKH; Ball JK; Patel AH
    J Gen Virol; 2008 Mar; 89(Pt 3):653-659. PubMed ID: 18272755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of the human antibody response to the neutralization epitopes encompassing amino acids 313-327 and 432-443 of hepatitis C virus E1E2 glycoproteins.
    Liu R; Rao H; Wang J; Xie X; Jiang D; Pan X; Zhao P; Zhang H; Wei L
    PLoS One; 2013; 8(6):e66872. PubMed ID: 23826163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
    Deng K; Liu R; Rao H; Jiang D; Wang J; Xie X; Wei L
    PLoS One; 2015; 10(9):e0138756. PubMed ID: 26406225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
    Swann RE; Cowton VM; Robinson MW; Cole SJ; Barclay ST; Mills PR; Thomson EC; McLauchlan J; Patel AH
    J Virol; 2016 May; 90(9):4530-4543. PubMed ID: 26912610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of neutralizing monoclonal antibodies against Hepatitis C virus E2 protein effectively blocks virus infection.
    Bose M; Mullick R; Das S; Das S; Karande AA
    Virus Res; 2016 Sep; 224():46-57. PubMed ID: 27574733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.